NexGel (NexGel) 5-Year EBITDA Growth Rate : -11.90% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexGel 5-Year EBITDA Growth Rate?

NexGel's EBITDA per Share for the three months ended in Mar. 2024 was $-0.13.

During the past 3 years, the average EBITDA Per Share Growth Rate was 21.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of NexGel was 21.10% per year. The lowest was -102.90% per year. And the median was -18.70% per year.

Competitive Comparison of NexGel's 5-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, NexGel's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexGel's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NexGel's 5-Year EBITDA Growth Rate falls into.

NexGel 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

NexGel (NAS:NXGL) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

NexGel 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NexGel's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NexGel (NexGel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047

Website

https://www.nexgel.com

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.

Executives

Steven Mark Glassman	director	99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein	director	QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry	director	34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky	director	850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad	director	3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii	officer: Chief Financial Officer	6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc	10 percent owner	C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy	officer: CEO and President	2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson	director, officer: Chief Executive Officer	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc.	10 percent owner	100 PINE ST., STE. 500, SAN FRANCISCO CA 94111